Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

NCT02621398 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT02621398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02621398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 1
Overall status
Completed
Start date
August 4, 2016
Completion date
February 29, 2024
Enrollment
23 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii non-small cell lung cancer, stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer